Navigation Links
Frost & Sullivan Finds the Entrenched Nature of qPCR Technology Sustains the US Reagents Market

MOUNTAIN VIEW, Calif., July 31, 2013 /PRNewswire/ -- Quantitative real-time polymerase chain reaction (qPCR) is a technique that has survived for decades, providing validated, publishable data for researchers and holding a favorable reputation for performance and sensitivity. This established technology, in turn, sustains the U.S. qPCR reagents market. As a result, the country's mature qPCR reagents market fared well through rough economic conditions.

According to the Frost & Sullivan analysis, U.S. qPCR Reagents Market, revenues are expected to grow from $650 million in 2012 to reach $858 million in 2017. The research, part of the Life Sciences ( Growth Partnership Service program, details market drivers and restraints, trends that will influence future market dynamics and competitive factors driving technology usage.

For more information on this research, please email Britni Myers, Corporate Communications, at, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"The expanding range of applications that utilize qPCR boost the qPCR reagents market as the continuous restocking of reagents is necessary for work to go on," said Frost & Sullivan Life Sciences Senior Industry Analyst Christi Bird. "Emerging high growth applications, including pharmacogenomics, and microRNA, non-coding RNA and epigenetics research, will add to the demand for qPCR reagents."

However, the market is restrained by maturity in established applications, high saturation and limited growth of qPCR instruments, as well as budget constraints, particularly in academic and government laboratories. Moreover, with several key qPCR patents expiring over the next five years and beyond, an increase in competition will drive down pricing as well as revenues. The problem is compounded when new vendors compete on price to acquire customers. This has already occurred in the SYBR green segment and is expected to spill over to other segments as important patents expire.

Nevertheless, qPCR will maintain its value due to its accuracy, sensitivity, reproducibility, and entrenched usage in molecular biology laboratories. Product specialization, such as the development of qPCR disease or pathway-based panels, microRNA or epigenetics products, and low-volume capabilities, will help thwart price erosion and support niche workflows.

"High quality suppliers should have little trouble maintaining customers, as performance, quality and comfort are still key purchasing factors for qPCR reagents," noted Bird. "Researchers in the United States are unwilling to sacrifice these features for price alone."

Frost & Sullivan's related Life Sciences research includes: Global Mass Spectrometry Market, Cell Culture Purchasing Trends, and Analysis of the Asia-Pacific Molecular Diagnostics Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare and LinkedIn, for the latest news and updates.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

U.S. qPCR Reagents Market

Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003

Twitter: @frost_sullivan
Facebook: Frost & Sullivan

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Hosts Analyst Briefing: An Outlook of Azerbaijan and Iran Healthcare Markets
2. Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
3. Market Insight: Irans Healthcare Market on the Rise -- Frost & Sullivan
4. Frost & Sullivan: SMBG Suppliers Look to Tap the Huge Underpenetrated Diabetic Population in Asia-Pacific
5. Patients and Physicians Express Desire to Switch to Transdermal Drug Delivery, Finds Frost & Sullivan
6. Frost & Sullivan: Physicians Focus on RCM Solutions to Prepare for New Wave of Financial Challenges
7. Frost & Sullivan: Expiration of Patents for Leading Drugs to Bolster the Oral Solid Drug Dosage Excipients Market in North America
8. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
9. Frost & Sullivan: mHealth Serves as the Catalyst for Healthcares Evolution
10. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
11. Global In Vitro Diagnostics Markets Outpace Pharma Industry Growth, finds Frost & Sullivan
Post Your Comments:
(Date:11/30/2015)... 2015  Precision Image Analysis Inc. (PIA), a ... announce a dramatic expansion of its capabilities as ... its ISO-9001:2008 certification for its Quality Management System, ... protocols and procedures. This expansion enables PIA to ... Core Lab services include design and optimization of ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 ... . --> Pharmaboardroom releases its new 98-page Mexico ... America , a country of over 122 million people. ... 122 million people. --> It offers companies, investors, policymakers, ... insights into the second largest pharma and healthcare market in ...
(Date:11/30/2015)... AVIV, Israel , November 30, 2015 ... ) ("Elbit" or the "Company") announced today that it was ... of Food and Drug Safety (MFDS) has approved its ... disorders. --> --> ... a non-invasive treatment alternative that combines two technologies: Focused ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation ... cancer education and prevention—is joining forces with the award-winning creator and writer of ... on December 7, 2015 at the Union League of Philadelphia. , The ...
(Date:11/30/2015)... ... 30, 2015 , ... While powdered supplements and drinks can reduce food preparation ... from Chesterfield, Va., has found an easy to keep track of the scoop. , ... powdered contents in a canister or other container handy and readily accessible. As such, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since ... websites specializing in independent living, assisted living and all other retirement options. Support ... awareness and research remains a top priority. , So it’s no ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New ... is so important to this key industry segment, Regis Technologies has decided to sponsor ... December 4th at 11am EST. , Federal law does not allow new drugs to ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability ... to the medical schools of the future. To reach an audience of key ... 2015 ChangeMedEd conference in Chicago, organized by the American Medical Association. , ...
Breaking Medicine News(10 mins):